P = 0.001, **p <0.P019 Relation between adrenomedullin and short-term outcome in ICU > 자유게시판

본문 바로가기
자유게시판

P = 0.001, **p <0.P019 Relation between adrenomedullin and short-te…

페이지 정보

작성자 Mackenzie 작성일24-04-27 09:51 조회4회 댓글0건

본문

P = 0.001, **p < 0.P019 Relation between adrenomedullin and short-term outcome in ICU patients: Results from the frog ICU study E. G. Gayat1, J. Struck2, A. Cariou3, N. Deye1, B. Guidet4, S. Jabert5, J. Launay1, M. Legrand6, M. L ne7, M. Resche-Rigon6, E. Vicaut1, A. Vieillard-Baron8, A. Mebazaa1 1 H ital Lenvatinib Lariboisi e, Paris, France; 2Sphingotec, Berlin, Germany; 3H ital Cochin, Paris, France; 4H ital Saint-Antoine, Paris, France; 5CHRU de Montpellier, Montpellier, France; 6H ital Saint-Louis, Paris, France; seven AP-HM, Marseille, France; 8H ital Ambroise Par? Paris, France Critical Care 2016, 20(Suppl 2):P019 Introduction: Adrenomedullin (ADM) is really a peptide with fifty two amino acids that has robust vasodilator activity. Elevated plasma ADM degrees have already been detected inside of a wide range of physiological and pathological situations, with PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/22763976 the highest elevations noticed in septic shock. Marino et al. demonstrated a robust association of admission ADM degrees with all the severity of sepsis, supporting an previously report describing elevated ADM ranges in these with significant sepsis and people with septic shock [1]. By making use of a novel assay specific for bioactive ADM (bio-ADM) as Marino et al.the purpose with the study was to assess the relation concerning ADM calculated at admission and in-ICU mortality in consecutive sufferers irrespective the reason for admission. Solutions: The French and euRopean Result reGistry in Intense Treatment Models (FROG-ICU) study was a multicenter observational examine, including 2087 consecutive patients followed up to one 12 months for those who survived to ICU continue to be. The protocol has earlier been explained [2]. Plasma were being gathered at admission for all clients and at discharge for in-ICU survivors. ADM was calculated in all plasma using a sandwich assay unique for bio-ADM. The association amongst inICU mortality as well as amount of ADM was assessed by univariate evaluation and altered analysis for severity at admission calculated with the SAPS-II. Advancement in place beneath the ROC curve and reclassification indices ended up assessed. Effects: 2087 clients happen to be bundled, sixty five male using a median age of sixty three (51-74), a median Charlson score of 3 (1-5) along with a median SAPS-II 49 (36-63). Septic shock was existing in 488 (23 ) clients. Median (and interquartile range) of ADM in-ICU survivors and nonsurvivors was 57 pg/mL [30-114] and one hundred ten pg/mL [63-220], respectively (p < 0.001). Hazard ratio of in-ICU death for patients with a level of ADM higher than the median value was 2.12 (95 CI: 1.73-2.60) and 1.68 (95 CI: 1.36-2.07) when adjusted for SAPS-II. Area under the ROC curve of SAPS-II was significantly improved by the addition of ADM (0.653 [0.624 - 0.682] to 0.702 [0.675 - 0.729], p = 0.01). Conclusions: In the present study, ADM was independently associated with in-ICU mortality and improved prognostic prediction. The clinical and therapeutic implication of these findings need to be further investigated.References [1] R Marino et al. Critical Care 2014, 18:R34 [2] Mebazaa et al. BMC Anesthesiology (2015) 15:P020 Impact of disease severity assessment on performance of heparinbinding protein for the prediction of septic shock R. Arnold1, M. Capan1, A. Linder2, P. Akesson2 1 Christiana Care Health System, Newark, USA; 2Skane University Hospital, Lund University, Lund, Sweden Critical Care 2016, 20(Suppl 2):PCritical Care 2016, Volume PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9547713 20 SupplPage twenty ofIntroduction: Prognostic biomarkers for sepsis are explained irrespective of affected individual severity. Our goal was to desc.

댓글목록

등록된 댓글이 없습니다.

회사명 방산포장 주소 서울특별시 중구 을지로 27길 6, 1층
사업자 등록번호 204-26-86274 대표 고광현 전화 02-2264-1339 팩스 02-6442-1337
통신판매업신고번호 제 2014-서울중구-0548호 개인정보 보호책임자 고광현 E-mail bspojang@naver.com 호스팅 사업자카페24(주)
Copyright © 2001-2013 방산포장. All Rights Reserved.

상단으로